Veru (NASDAQ:VERU) Trading 7% Higher

Shares of Veru Inc (NASDAQ:VERU) traded up 7% during mid-day trading on Wednesday . The stock traded as high as $2.49 and last traded at $2.45, 660,090 shares were traded during mid-day trading. An increase of 321% from the average session volume of 156,756 shares. The stock had previously closed at $2.29.

Several equities research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $4.50 price target on shares of Veru in a research note on Friday. ValuEngine upgraded Veru from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Finally, Zacks Investment Research cut Veru from a “hold” rating to a “sell” rating in a research note on Saturday, October 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $5.71.

The firm has a 50 day simple moving average of $2.07 and a two-hundred day simple moving average of $2.06. The company has a quick ratio of 1.20, a current ratio of 1.47 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $156.74 million, a P/E ratio of -6.18 and a beta of 0.38.

Veru (NASDAQ:VERU) last released its earnings results on Thursday, December 12th. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). Veru had a negative return on equity of 50.14% and a negative net margin of 59.68%. The firm had revenue of $8.73 million during the quarter, compared to analysts’ expectations of $9.26 million. On average, research analysts predict that Veru Inc will post -0.19 earnings per share for the current year.

In other Veru news, CEO Mitchell Shuster Steiner sold 25,000 shares of the company’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $2.27, for a total transaction of $56,750.00. Insiders have sold 80,000 shares of company stock valued at $170,458 over the last 90 days. Corporate insiders own 29.50% of the company’s stock.

Large investors have recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Veru by 65.4% during the second quarter. BlackRock Inc. now owns 228,934 shares of the company’s stock worth $487,000 after buying an additional 90,530 shares in the last quarter. Wedge Capital Management L L P NC acquired a new position in shares of Veru during the second quarter worth $394,000. Renaissance Technologies LLC increased its holdings in shares of Veru by 183.1% during the second quarter. Renaissance Technologies LLC now owns 262,160 shares of the company’s stock worth $558,000 after buying an additional 169,550 shares in the last quarter. Tower Research Capital LLC TRC acquired a new position in shares of Veru during the third quarter worth $25,000. Finally, Perceptive Advisors LLC increased its holdings in shares of Veru by 1.4% during the second quarter. Perceptive Advisors LLC now owns 1,445,000 shares of the company’s stock worth $3,078,000 after buying an additional 20,000 shares in the last quarter. Institutional investors own 9.76% of the company’s stock.

Veru Company Profile (NASDAQ:VERU)

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Further Reading: What are the qualifications of a portfolio manager?

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.